Host: |
Goat |
Applications: |
Pep-ELISA |
Reactivity: |
Human/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Goat polyclonal antibody anti-TFAP2D (70-82) is suitable for use in ELISA research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
Concentration: |
0.5 mg/mL |
Dilution Range: |
ELISA-antibody detection limit dilution 1:2000. |
Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
Gene Symbol: |
TFAP2D |
Gene ID: |
83741 |
Uniprot ID: |
AP2D_HUMAN |
Immunogen Region: |
70-82 |
Accession Number: |
NP_758438.2 |
Immunogen Sequence: |
HHQSFHYEFQHSH |
Function | Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. |
Protein Name | Transcription Factor Ap-2-DeltaAp2-DeltaActivating Enhancer-Binding Protein 2-DeltaTranscription Factor Ap-2-Beta-Like 1 |
Database Links | Reactome: R-HSA-8866904Reactome: R-HSA-8866907 |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Transcription Factor Ap-2-Delta antibodyAnti-Ap2-Delta antibodyAnti-Activating Enhancer-Binding Protein 2-Delta antibodyAnti-Transcription Factor Ap-2-Beta-Like 1 antibodyAnti-TFAP2D antibodyAnti-TFAP2BL1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance